As a co-inventor of the technology used at C2i Genomics, Asaf led the company development from academy research concept to VC-backed growth-stage company. Dr. Zviran brings over 15 years of R&D management in life science and defense, including numerous high impact scientific publications and patents. As a former cancer survivor, Asaf is committed to improving cancer patients’ quality of life and outcomes.
C2informed: AI-Based Whole Genome Sequencing of ctDNA
C2informed is a personalized tumor-informed assay for molecular residual disease (MRD) detection in oncology. This test uses whole-genome sequencing (WGS), and by advanced bioinformatics and artificial intelligence technology, the C2informed enables precision MRD monitoring, for early detection of recurrence and disease surveillance, even in the setting of a low-burden disease.
Track Chair: Cindy Lawley, Olink